A Male patient with myocardial infarction as a frst manifestation of antiphospholipid syndrome - Treatment with rivaroxaban;Chory po zawale serca jako pierwszej manifestacji zespolu antyfosfolipidowego - leczenie riwaroksabanem

Kardiologia Polska

Volumn 74, Issue , 2016, Pages 19-22

  Bryk, Agata ^a,b   Undas, Anetta ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Antiphospholipid syndrome; Myocardial infarction; Rivaroxaban; Venous thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; RIVAROXABAN; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN ISCHEMIA; CASE REPORT; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LEG THROMBOSIS; MALE; OBESITY; PARTIAL THROMBOPLASTIN TIME; RECURRENT DISEASE; RISK FACTOR; SMOKING;

EID: 85008975667     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.2016.0074     Document Type: Article

References (10)

1. Undas A, Pasierski T, Windyga J, Crowther M. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn, 2014; 124: 124-135.
2. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012; 366: 1287-1297.
3. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost, 2006; 4: 295-306.
4. Noel N, Dutasta F, Costedoat-Chalumeau N et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev, 2015; 14: 680-685.
5. Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis, 2015; 26: 476-477.
6. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol, 2014; 89: 1017.
7. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res, 2015; 135: 1035-1036.
8. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol, 2016; 35: 801-805.
9. Cervera R, Khamashta MA, Shoenfeld Y et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis, 2009; 68: 1428-1432.
10. Perl L, Netzer A, Rechavia E et al. Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention. Cardiology, 2012; 122: 76-82.